Literature DB >> 14519434

Differential coupling of m-cholinoceptors to Gi/Go-proteins in failing human myocardium.

Clemens Mittmann1, Gunnar Pinkepank, Sophia Stamatelopoulou, Thomas Wieland, Bernd Nürnberg, Stefan Hirt, Thomas Eschenhagen.   

Abstract

Muscarinic acetylcholine receptors (mAChRs) mediate their main cardiac effects via pertussis toxin-sensitive G-proteins. Physiological effects differ considerably between atrium and ventricle, and it is unknown to which extent these differences derive from selective receptor-G-protein coupling or further downstream events. We have characterized specific coupling between mAChRs and Gi/Go-protein isoforms in atrial and ventricular myocardium by agonist-dependent photoaffinity labeling with [(32)P]azidoanilido GTP (aaGTP) and immunoprecipitation in sarcolemmal membranes from terminally failing human hearts. The total amount of mAChRs, as determined by specific binding of [(3)H]QNB, was significantly higher in right-atrial (RA +/- SEM, 959 +/- 68 fmol/mg, n = 4) than in left-ventricular membranes (LV, 582 +/- 53 fmol/mg, n = 6). Standardized immunoblots revealed that Gialpha-2 was the predominant subtype in both regions. A 40-kDa splice variant of Goalpha (Goalpha-1 and/or Goalpha-3) was almost exclusively detectable in RA. Levels of Gialpha-3 and a 39-kDa splice variant of Goalpha (Goalpha-2) were also higher in RA. Basal aaGTP binding was higher in RA than in LV for all Gialpha/Goalpha subtypes. The carbachol (10 micromol/l)-induced increase in aaGTP binding was significantly higher in RA than in LV for Goalpha-1/3 (336 +/- 95% of LV, n = 4) and for Gialpha-3 (211 +/- 83%), lower for Gialpha-2 (42 +/- 5%), and was similar in both regions for Goalpha-2 (130 +/- 62%). The differential coupling of mAChRs in human RA and LV suggests that the initiation of different physiological responses to mAChR stimulation starts with signal sorting at the receptor-G-protein level.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519434     DOI: 10.1016/s0022-2828(03)00235-9

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  6 in total

Review 1.  Myths and realities of the cardiac vagus.

Authors:  J H Coote
Journal:  J Physiol       Date:  2013-07-22       Impact factor: 5.182

2.  Competition for Gβγ dimers mediates a specific cross-talk between stimulatory and inhibitory G protein α subunits of the adenylyl cyclase in cardiomyocytes.

Authors:  Hans-Jörg Hippe; Mark Lüdde; Katrin Schnoes; Ana Novakovic; Susanne Lutz; Hugo A Katus; Feraydoon Niroomand; Bernd Nürnberg; Norbert Frey; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-26       Impact factor: 3.000

3.  Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation.

Authors:  Gary L Aistrup; Roger Villuendas; Jason Ng; Annette Gilchrist; Thomas W Lynch; David Gordon; Ivan Cokic; Steven Mottl; Rui Zhou; David A Dean; J Andrew Wasserstrom; Jeffrey J Goldberger; Alan H Kadish; Rishi Arora
Journal:  Cardiovasc Res       Date:  2009-05-20       Impact factor: 10.787

4.  Gαi2- and Gαi3-specific regulation of voltage-dependent L-type calcium channels in cardiomyocytes.

Authors:  Sara Dizayee; Sonja Kaestner; Fabian Kuck; Peter Hein; Christoph Klein; Roland P Piekorz; Janos Meszaros; Jan Matthes; Lutz Bjrnbaumer; Bernd Nürnberg; Stefan Herzig
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

5.  RGS3L allows for an M2 muscarinic receptor-mediated RhoA-dependent inotropy in cardiomyocytes.

Authors:  Susanne Lutz; Thomas Wieland; Magdolna K Levay; Kurt A Krobert; Andreas Vogt; Atif Ahmad; Andreas Jungmann; Christiane Neuber; Sebastian Pasch; Arne Hansen; Oliver J Müller
Journal:  Basic Res Cardiol       Date:  2022-03-01       Impact factor: 12.416

6.  Analyses of Gnai3-iresGFP reporter mice reveal unknown Gαi3 expression sites.

Authors:  Veronika Leiss; Ellen Reisinger; Annika Speidel; Sandra Beer-Hammer; Bernd Nürnberg
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.